EMEA-001407-PIP03-20

Table of contents

Key facts

Invented name
Opdivo
Active substance
nivolumab
Therapeutic area
Oncology
Decision number
P/0280/2020
PIP number
EMEA-001407-PIP03-20
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of all conditions in the category of malignant neoplasms (except central nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms other than Hodgkin lymphoma)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG

E-mail: medical.information@bms.com
Tel: +44 1423533610

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating